Drug Profile
Nerve growth factor - Sinobioway Bio-medicine
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Xiamen Bioway Biotech
- Developer Sinobioway Bio-medicine; The Second Affiliated Hospital of Zhejiang University School of Medicine
- Class Foot disorder therapies; Nerve growth factors; Neuroprotectants
- Mechanism of Action Neuron stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Optic nerve disorders
- Phase II Diabetic foot ulcer
- No development reported Brain disorders; Spinal muscular atrophy
Most Recent Events
- 25 Feb 2021 Phase II development for Diabetic foot ulcer (In adults, In the elderly) is still ongoing in China (ChiCTR1800016368)
- 01 Jan 2018 Phase-II clinical trials in Diabetic foot ulcer (In adults, In the elderly) in China (Parenteral) (ChiCTR1800016368)
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Brain-disorders(In infants) in China (Parenteral, Injection)